MANNKIND CORP Gain (Loss) on Extinguishment of Debt
MANNKIND CORP (MNKD) reported Gain (Loss) on Extinguishment of Debt of -$917.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-05
- MANNKIND CORP gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- MANNKIND CORP gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was -$917.00K.
- MANNKIND CORP gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was -$13.39M.
- MANNKIND CORP gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- MANNKIND CORP gain (loss) on extinguishment of debt for fiscal 2024 was -$20.44M.
- MANNKIND CORP gain (loss) on extinguishment of debt for fiscal 2021 was -$17.20M.
- MANNKIND CORP gain (loss) on extinguishment of debt for fiscal 2020 was -$264.00K, a 107.48% decline from fiscal 2019.
- MANNKIND CORP gain (loss) on extinguishment of debt for fiscal 2019 was $3.53M.
| Period end | Gain (Loss) on Extinguishment of Debt 0 month | Gain (Loss) on Extinguishment of Debt | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$917.00K 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | -$917.00K 10-Q · filed 2026-05-06 | |||||
| 2024-12-31 | -$13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$13.39M derived: sum of 2 quarters · filed 2026-02-26 | -$20.44M derived: sum of 3 quarters · filed 2026-02-26 | -$20.44M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$7.05M derived: sum of 2 quarters · filed 2025-11-05 | -$7.05M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$7.05M 10-Q · filed 2025-08-06 | -$7.05M 10-Q · filed 2025-08-06 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.93M derived: sum of 2 quarters · filed 2024-02-27 | -$17.20M derived: sum of 3 quarters · filed 2024-02-27 | -$17.20M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $4.93M 10-Q · filed 2022-11-08 | -$17.20M derived: sum of 2 quarters · filed 2022-11-08 | -$17.20M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$22.13M 10-Q · filed 2022-08-09 | -$22.13M 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | -$264.00K 10-K · filed 2023-02-23 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.53M derived: sum of 2 quarters · filed 2021-02-25 | $3.53M 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $3.53M 10-Q · filed 2020-11-04 | $3.53M 10-Q · filed 2020-11-04 | ||||
| 2019-08-06 | $3.10M 10-Q · filed 2019-11-08 | $3.10M 10-K · filed 2020-02-25 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$712.00K derived: sum of 2 quarters · filed 2020-02-25 | $60.00K derived: sum of 3 quarters · filed 2020-02-25 | -$765.00K 10-K · filed 2020-02-25 | ||
| 2018-09-30 | -$712.00K 10-Q · filed 2019-11-08 | $60.00K derived: sum of 2 quarters · filed 2019-11-08 | -$765.00K 10-Q · filed 2019-11-08 | -$1.55M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $772.00K 10-Q · filed 2019-08-07 | -$53.00K 10-Q · filed 2019-08-07 | -$834.00K derived: sum of 3 quarters · filed 2019-08-07 | -$834.00K derived: sum of 4 quarters · filed 2019-08-07 | ||
| 2018-03-31 | -$825.00K 10-Q · filed 2019-05-07 | -$1.61M derived: sum of 2 quarters · filed 2019-05-07 | -$1.61M derived: sum of 3 quarters · filed 2019-05-07 | -$2.44M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | -$781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$781.00K derived: sum of 2 quarters · filed 2019-02-26 | -$1.61M derived: sum of 3 quarters · filed 2019-02-26 | -$1.61M 10-K · filed 2019-02-26 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$830.00K derived: sum of 2 quarters · filed 2018-11-01 | -$830.00K 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | -$830.00K 10-Q · filed 2018-08-02 | -$830.00K 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | $72.02M 10-K · filed 2019-02-26 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$1.05M derived: sum of 2 quarters · filed 2018-02-27 | -$1.05M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$1.05M 10-Q · filed 2016-11-09 | -$1.05M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |